A therosclerosis is a chronic inflammatory process characterized by the accumulation of lipids, inflammatory cells and fibrous elements in the arterial wall. Increased serum cholesterol levels and especially "bad" low-density lipoprotein (LDL) cholesterol in the form of oxidized low-density lipoproteins (oxLDL) are believed to play a key role during all stages of the disease by regulating the expression of chemokines and proinflammatory cytokines. Despite intense research efforts, the precise mechanisms leading to development and progression of atherosclerotic lesions remain largely unknown. This also applies to the still incomplete picture of the lesion-mediated regulation of growth factors and, in particular, their functions for lesion development. In this context, growth-differentiation factor (GDF)-15 has been suggested as a biomarker for cardiovascular diseases.
1 GDF-15 is a distant and divergent member of the transforming growth factor (TGF)-b superfamily, which does not belong to one of the TGF-b subfamilies. [2] [3] [4] [5] GDF-15 has been cloned and characterized in our and several other laboratories. [3] [4] [5] The protein is identical to (1) macrophage-inhibitory cytokine-1, (2) NSAID-activated gene-1, (3) placental bone morphogenetic protein-which all have been found in macrophages (MФ)-and to some other published sequences. [6] [7] [8] We and others have shown that GDF-15 is a lesion-induced factor implicated in a number of pathophysiological processes upstream regulators, and functional effects of GDF-15 in the cardiovascular system have not been elucidated. 11 A major still unresolved problem is the identification of GDF-15 specific receptor(s) and signalling pathways. In this context, several studies have suggested that GDF-15 signal transduction is mediated through classic TGF-b receptors and according downstream (ie, Smad) cascades. 15, 16 However, studies in our laboratory so far failed to confirm GDF-15 signaling via TGF-b (or glial cell line-derived neurotrophic factor [GDNF]) receptors (Strelau, 2004 , unpublished results). Development and progression of atherosclerotic plaques are driven by endothelial dysfunction, oxLDL deposition in the subendothelial space, and recruitment as well as attachment of inflammatory monocytes to the arterial vessel wall, their differentiation into MФ, and subsequent transformation into cholesterol-laden foam cells in the subendothelial space. We have previously reported that GDF-15 immunoreactivity is localized in MФ of human atherosclerotic carotid arteries and colocalizes with oxLDL, as well as apoptosis-relevant proteins. 17 Furthermore, we have shown that induction of apoptosis in cultured MФ (eg, by oxLDL) correlates with increased GDF-15 expression. 17 In addition, GDF-15 expression is increased after stimulation by proinflammatory cytokines such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b, or IL-6 but not by interferon-c and lipopolysaccharide. 2 We show here that GDF-15 expression (RNA and protein) is highly upregulated in the atherosclerotic vessel wall. Consistently, lack of GDF-15 revealed a significant long-term reduction of atherosclerotic lesion formation. This effect was accompanied by decreased occurrence of inflammatory CD11b + or IL-6 + leukocytes, apoptotic cell death; however, an increased percentage of MФ and enhanced cell density in atherosclerotic lesions of the innominate artery (=brachioce-phalic trunk) suggested that GDF-15 is involved in orchestrating atherosclerotic lesion progression.
Methods Animals
GDF-15 knockout/lacZ knockin (GDF-15 À/À ) mice 18 were crossbred with apolipoprotein (apo)E knockout (apoE À/À ) mice (Charles River, Sulzfeld, Germany). Male homozygous null and wild-type (WT) mice were used for experiments. All animal experiments were approved by the Regierungspr€ asidium Karlsruhe and the local authorities at the University of Heidelberg and were done in compliance with the regulations for animal studies at the University of Heidelberg.
Genotyping
Genomic DNA was isolated, according to the manufacturer's instructions (DNA Extraction Solution; Epicentre Biotechnologies, Madison, WI). Transgenic positive animals were identified by polymerase chain reaction (PCR) of genomic tail DNA, using intron-spanning oligonucleotides (Table 1) . PCR analysis showed representative single bands for GDF-15 
Isolation of Peritoneal Macrophages and Real-Time PCR (qRT-PCR)
To obtain an increased number of peritoneal macrophages, mice were injected with 500 lL of pristane (Sigma-Aldrich, Steinheim, Germany) into the lower left quadrant of the abdominal cavity perpendicularly to the fold for no more than 0.5 cm of the needle. After 2 days, mice were killed by cervical dislocation and peritoneal cells were removed by peritoneal lavage with 6 mL of ice-cold PBS buffer. Collected cells were washed twice with PBS and resuspended in RPMI medium containing 10% FBS, 1% penicillin-streptomycinneomycin, and 1% glutamine. After 1 hour (37°C, 5% CO 2 ), nonadherent cells were discarded. Adherent cells were incubated overnight before being exposed to native LDL 100 ng/mL, oxLDL 100 ng/mL, or medium alone for 12 hours. Subsequently, the cells were washed and extraction of total RNA was performed using TriFast solution (PeqLab, Erlangen, Germany) according to the manufacturer's standard protocol. Tissue samples were transferred immediately after preparation into RNA-later-ICE (Ambion, Austin, TX) and homogenized in Precellys tubes with ceramic beads in a Precellys homogenizator (PeqLab). Total RNA extraction was performed according to the manufacturer's instructions (TriFast; PeqLab).
RNA concentration and purity were determined by A260 and A280 (A260/A280=1.7 to 2.0) measurements using a NanoDrop 8000 Spectrophotometer (Thermo Scientific, Schwerte, Germany). Total RNA integrity was confirmed using lab-on-a-chip technology, using an RNA 6000 NanoChip kit on an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). RNA was pooled from at least 3 mice for each treatment and genotype. The RNA was dissolved in nuclease-free water (Invitrogen, Paysley, UK) and reverse transcribed using the Superscript III First Strand Synthesis System for RT-PCR (Invitrogen) and oligo (dT) [12] [13] [14] [15] [16] [17] [18] primers according to the manufacturer's specifications. The cDNA was used for qRT-PCR analysis using the QuantiTect/PrimerAssays (Qiagen GmbH, Hilden, Germany).
The cDNA were amplified by qRT-PCR using brilliant II SYBR Green QRT-PCR Master Mix (Stratagene-Agilent Technologies, Waldbronn, Germany). The thermal profile consisted of 1 cycle at 50°C for 2 minutes followed by 1 cycle at 95°C (2 minute), 45 cycles at 95°C (15 seconds), 60°C (1 minute). Amplification was conducted using the M93005P QPCR System (Stratagene-Agilent Technologies). Data were analyzed using the M93005P analysis software (Stratagene-Agilent). Relative quantity was calculated by the comparative CT method where the amount of the target gene, normalized to the reference gene and relative to a calibrator (WT expression or control without treatment) is given by 2
ÀΔΔCT . For details of the oligonucleotides used for qRT-PCR, please refer to Table 2 .
Animal Study and Blood Samples
At an age of 9 weeks, the offspring were fed with an adjusted-calories cholesterol-enriched diet (CED, TD.88137; Harlan Teklad, Madison, WI) for a period of 12 or 20 weeks. Body weight and blood samples were taken before and after 
Gel Electrophoresis and Immunoblot Analyses
Protein extraction of the protein phase mentioned earlier was performed according to the manufacturer's instructions (TriFast, PeqLab). Twenty-five micrograms of protein extract per lane was loaded on 14% SDS-polyacrylamide gels and transferred to PVDF membranes (Immobilon-P; Millipore, Billerica, MA) by electroblotting. Recombinant GDF-15 protein and antibodies are described in Table 3 . Bound antibodies were detected with peroxidase-conjugated secondary antibodies and ECL Plus Western blotting substrate system (GE Healthcare) according to the manufacturer's manual.
Morphometry and Immunohistology
For morphometric and immunohistological investigations, tissue samples were taken 24 hours after PET as described earlier. The aorta ascendens, aortic arch, and the innominate artery were removed and shock-frozen in liquid nitrogen-cooled isopentane. The extent of atherosclerotic plaques was morphometrically measured in the aorta ascendens and the innominate artery by computer-assisted morphometry. Immunohistochemical examination of mouse innominate artery was routinely performed according to methods described earlier, 17 using antibodies as described in Table 3 .
Statistical Analysis
The normality and variance of data were analyzed using the On stimulation with oxLDL, MФ synthesize a variety of proinflammatory cytokines and proapoptotic proteins. 20 We used cultured peritoneal MФ from GDF-15
GDF-15
+/+ /apoE À/À , and WT mice to assess the effect of oxLDL on GDF-15, IL-6, IL-1b, and caspase-3 mRNA expression. MФ from WT or GDF-15
8-fold or, respectively, 9-fold increased GDF-15 expression levels ( Figure 1A ). Notably, oxLDL induced the expression of the proinflammatory cytokine, IL-6 (5-fold) in peritoneal MФ of GDF-15 Figure 1B ). IL-1b mRNA levels were also increased in GDF-15 Relative expression (arbitrary units) death, we next compared the expression levels of the proapoptotic gene caspase-3 in peritoneal MФ in presence and absence of GDF-15. Consistent with a proapoptotic effect of GDF-15 caspase-3 mRNA levels where 1.9-fold increased in GDF-15 +/+ /apoE À/À mice ( Figure 1D ).
Incubation of GDF-15
with exogenous GDF-15 and oxLDL induced a significant increase of IL-6 expression, whereas IL-1b and caspase-3 transcripts remained unaltered in this experimental setting ( Figure 2 ). These findings argue in favor of a direct effect of GDF-15 on IL-6 expression, whereas the observed reduction in oxLDL induced IL-1b and caspase-3 expression are indirectly affected by GDF-15 deficiency.
GDF-15 Is Upregulated in the Atherosclerotic Vessel Wall
We have shown previously that GDF-15 is expressed in MФ of human atherosclerotic lesions. 17 We therefore started to determine whether GDF-15 mRNA and protein levels are affected in experimental atherosclerosis. WT and GDF-15
apoE À/À male mice were maintained on a CED for 12 or 20 weeks starting at an average age of 9 weeks. Figure 3A and 3B show the GDF-15 mRNA expression and protein levels in the aortic arch including the innominate artery. Normalized to the low expression levels in WT mice, GDF-15 mRNA was 2.6-fold (12 weeks) and 6.8-fold (20 weeks) increased in apoE À/À mice ( Figure 3A) . Consistently, GDF-15 protein immunoreactivity was exclusively detected in apoE-deficient mice after 20 weeks on CED ( Figure 3B ). Together, these results suggest that development of atherosclerotic lesions is paralleled by a significant increase in GDF-15 expression on mRNA and protein levels. was even more pronounced in animals with an apoE : 83 mg/dL). Cholesterol levels in both groups fed with CED for 12 or 20 weeks were not significantly different (Table 4) . Loss of apoE per se resulted in a 2-to 3-fold increase in plasma cholesterol levels in comparison to apoE-competent mice (Table 4) . apoE knockout mice lacking GDF-15 displayed additional significantly elevated blood cholesterol levels before and after 12 weeks feeding CED (GDF-15 À/À /apoE À/À : 284 and 755 mg/dL vs 18 FDG were performed in animals 24 hours before the aorta ascendens and aortic arch were removed and shockfrozen in liquid nitrogen-cooled isopentane. A, The extent of the atherosclerotic plaque was morphometrically measured in the aortic arch by computer-assisted morphometry. GDF-15 deficiency reduced lumen stenosis in the aortic arch by 52% (GDF-15 À/À /apoE-15 observed in the aortic arches of these animals, lumen stenosis in GDF-15-deficient mice was significantly lower after 20 weeks of CED (51.9% vs 66.3%; Figure 5A ).
GDF-15-
Because we have shown previously that GDF-15 may regulate inflammatory cell migration, differentiation, and maturation, we determined the number of inflammatory cells in atherosclerotic lesions of the innominate artery ( Figure 5B and 5C). Figure 5B ). The percentage of IL-6 immunoreactive cells in atherosclerotic lesions of apoE-deficient mice was not affected by the absence of GDF-15 after 12 weeks of CED ( Figure 5C and 5D). However, while the IL-6 immunoreactive area more than doubled from 12 to 20 weeks in GDF-15 +/+ /apoE À/À mice, there was only a marginal increase in GDF-15
Our previous studies demonstrated that the induction of GDF-15 expression by oxLDL coincides with an increased rate of apoptosis in MФ. 17 Since we found a significantly reduced lumen stenosis in GDF-15 À/À /apoE À/À mice after 20 weeks of feeding CED, we analyzed whether the reduction might be due to changes in the rate of apoptosis. Figure 5E ). This difference was further increased to 74% after 20 weeks (3.6% vs 13.8%; Figure 5E and 5F). Because both apoptosis and autophagy are involved in cell death processes, we additionally used antibodies directed against the apoptosis specific protein APG5L/ATG, which is required for autophagy. Loss of GDF-15 had no effect on APG5L/ATG + cells in atherosclerotic lesions after 12 weeks of CED. However, there was a significant reduction in the number of APG5L/ ATG + cells after 20 weeks of CED (36.0% vs 52.7%; Figure 5G was no difference in the percentage of a-actin-positive smooth muscle cells in both groups ( Figure 6C ). As atherosclerotic plaques containing a high number of MФ are less stable, we determined the percentage of MФ in atherosclerotic lesions of the innominate artery using CD68 and MoMa-2 (Monocytes/Macrophages-2) antibodies ( Figure 6D and 6E). After 12 weeks of CED, we found no quantitative differences between GDF-15 17 We show here that GDF-15 deficiency results in the inhibition of proapoptotic and the induction of antiapoptotic genes in peritoneal MФ after oxLDL exposition in vitro. These data are in accordance with our in vivo findings showing a reduction in TUNEL-or APG5L/ATG-positive cells in atherosclerotic lesions of double knockout mice confirming the assumption that GDF-15 may be important in MФ death in atherosclerotic lesions as has been postulated by others. 36, 38 Indeed, inhibition of autophagy, evaluated by APG5L/ATG, seems to parallel the (partly significant) inhibition of plaque development (as indicated by lumen stenosis) after 12 or 20 weeks of CED. Therefore, significant reduction in percentage of CD11b, IL-6, TUNEL, or APG5L/ATG cells, which are in particular seen after 20 weeks of CED, seem to be responsible for the inhibition of atherosclerosis progression after 20 weeks of CED. Here we show for the first time that GDF-15 deficiency results in inhibition of atherosclerosis progression in hypercholesterolemic mice despite an inhibition of apoptotic processes and an increase in cell density in atherosclerotic lesions. This implicates that inhibition of apoptosis is antiatherogenic and may be a therapeutic strategy to control plaque progression. In detail, the diminished progression of atherosclerosis, indicated by decreased lumen stenosis in GDF-15 À/À /apoE À/À mice, may be the consequence of alterations in apoptotic processes, proliferation, and number of MФ or SMC in atherosclerotic lesions. In the present study, the increased cell density in atherosclerotic lesions of the innominate artery of GDF-15 À/À /apoE À/À mice is due to an increased number of MФ (CD68 + , MoMa-2 + )
rather than to alterations in the number of smooth muscle cells or cell proliferation, suggesting that GDF-15 is involved in orchestrating atherosclerotic lesion progression. In contrast to the increase of CD68 + and MoMa-2 + in GDF-15 À/À / apoE À/À mice, the number of CD11b-positive cells is significantly reduced. These observations indicate that this reduction may for the most part contribute to the inhibition of atherosclerotic lesion progression. In this context, it is interesting to mention that LDL has been shown to stimulate CD11b expression in monocytes. 38 Moreover, downregulation of these cells in obese animals significantly increases inflammation 39 and CD11b is upregulated on monocytes after adipose tissue transplantation in addition with a dominant expression of the inflammatory cytokine IL-6. 40 In contrast, the number of leukocytes expressing proinflammatory cytokines COX-2 and MIF is elevated in atherosclerotic lesions. These data suggest that, independent of increased serum lipid levels, GDF-15 may-to a certain extentpositively regulate CD11b and inversely regulate COX-2 and MIF. Indeed, drug experiments using, for example, NSAIDs, revealed that GDF-15 and COX-2 expression are inversely regulated. 41 Furthermore, our data support the notion that increased numbers of COX-2 + cells in atherosclerotic lesions of GDF-15
/apoE À/À may play an antiatherosclerotic role, as already supposed by others. 42 Conversely, it has been demonstrated that COX-2 deficiency results in a marked elevation of proinflammatory cytokines like IL-6. 42 Our data suggest that IL-6 plays a major role in the progression of atherosclerosis and is a putative target of GDF-15. We and others have shown that under physiological conditions, GDF-15 is-if at all-only expressed at (very) low levels in, for example, human macrophages 10, 17, 19 or in the vessel wall. 29 Moreover, GDF-15 expression is induced in vitro and in vivo under (oxidative) stress conditions, such as incubation of human macrophages with retinoic acid/phorbol ester 10 or with oxLDL, C6-ceramide, TNF-a, or H 2 O 2 , 17 whereby the last 3 substances have been shown to act as mediators of mechanisms relating to signal transduction activated by oxLDL. 19 In this context, we show here that GDF-15 is upregulated in the atherosclerotic vessel wall and most recent reports reveal evidence that GDF-15 is associated with infarct size in experimental heart attack models and involved in the immigration of leukocytes into injured tissue. 43 Thus, GDF-15 may be a novel powerful biomarker for cardiovascular diseases such as heart attack or atherosclerosis. This hypothesis is further supported by recent studies on the association of GDF-15 and coronary diseases as published by the Dallas Heart Study. 44 Moreover, our findings and the data recently published 27 on the functional proatherogenic role of GDF-15 in lesion progression indicate that beside other TGF-b superfamily members such as TGF-b1 and BMP, 45, 46 interference with GDF-15 may be a useful novel strategy for therapeutical intervention.
